1st Circ. Loss Dooms New Asacol Buyer Class, Allergan Says
By Chris Villani · March 21, 2019, 6:36 PM EDT
Allergan PLC said a group that claims the company's anti-competitive methods caused it to overpay for its ulcerative colitis drug should not get a second chance at class certification after the...
To view the full article, register now.